A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,